Clinical Trial

Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma

Study acronym: IDRIS
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated December 23, 2022 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of the trial is to establish whether adjuvant therapy with lenalidomide + dexamethasone after radiotherapy can improve progression free survival in patients with high risk solitary bone plasmacytoma compared with RT only.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2015-09-04; most recent amendment 2022-12-22.
Status change: Recruiting → Active, Not Recruiting 2021-05-17
Status change: Not Yet Recruiting → Recruiting 2017-04-28
Trial Details
NCT Number NCT02544308
Lead Sponsor University College, London
Collaborators: Cancer Research UK, Celgene
Conditions Plasmacytoma
Enrollment 36 participants
Start Date 2017-03-10
Primary Completion 2026-04 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2022-12-23